



GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

File No. CT/23/000014

To,

M/s Pharmaceutical Research Associates India Private Limited,
Regus Kaledonia, Unit No 1B, Office No 538, 05th Floor, Sahar Road,
Off Western Express Highway, Andheri East, Mumbai, Maharashtra (India) - 400059.

Sir,

With reference to your application No. GCT/CT04/FF/2023/36174 (GCT/14/23) dated 17-02-2023, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease in Adults Aged 60 Years And Older with a History of Urinary Tract Infection in the Past 2 Years”**, Protocol No.: VAC52416BAC3001, Version No. Amendment 5 Dated 02-DEC-2022 with a total of up-to 450 subjects from India under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- (i) **Only CDL-Kasauli certified batches of IP shall be used in the Clinical Trial;**
- (ii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (iii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (iv) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

- (v) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (vi) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial
- (vii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (viii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (ix) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (x) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (xi) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xvi) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xviii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

- (xix) Merely granting permission to conduct the clinical trial with the Investigational Drug Product does not convey or imply that, based on the clinical trial study data generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- (xx) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

RAJEEV SINGH
RAGHUVANSHI
HI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL, ou=DRUGS CONTROLLER GENERAL
RAGHUVANSHI, email=rajeev.singh@cdco
769041015a06564fe67f54b765db1cb,
postalCode=600016, serialNumber=657F5E47D940985D8F03BDC902
DOE1FE73CFA12A1A126EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.07.14 15:55:28 +05'30'

Dr. Rajeev Singh Raghuvanshi
Drugs Controller General (India) &
Central Licencing Authority
Stamp

FORM CT-06

(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby **M/s. Pharmaceutical Research Associates India Private Limited, Regus Kaledonia, Unit No 1B, Office No 538, 05th Floor, Sahar Road Off Western Express Highway, Andheri East Mumbai (India) - 400059 Telephone No.: 4449032003 FAX: 22 71234198 E-Mail: REGULATORYAFFAIRSIND@ICONPLC.COM** to conduct clinical trial of the new drug or investigational new drug as per **Protocol No.: VAC52416BAC3001, Version No. Amendment 5 Dated 02-DEC-2022** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

RAJEEV SINGH
RAGHUVANSHI
HI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, st=TAMIL NADU,
RAGHUVANSHI,
2.5.4.20.6006216132e444f8e8a29977cdeb93e23d
904013006948e7154b7c2ab1c0,
postalCode=600034, st=TAMIL NADU,
serialNumber=657136E009408650F136C110030
E1FE73CFA12A1A126EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.07.14 15:55:41 +05'30'

Dr. Rajeev Singh Raghuvanshi
Drugs Controller General (India) &
Central Licensing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	EcoO15E+EcoO16E+EcoO18AE+EcoO1AE+EcoO25BE+EcoO2E+EcoO4E+EcoO6AE+EcoO75E
Therapeutic class:	Vaccine
Dosage form:	Solution for Injection
Composition:	EcoO1AE+EcoO2E+EcoO4E+EcoO6AE+EcoO15E+EcoO16E+EcoO18AE+EcoO25BE+EcoO75E = 176.0000 µg/ml Not Applicable (NA) Active
Indications:	Prevention of Invasive Extraintestinal Pathogenic Escherichia coli Disease

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	S.R. Kalla Memorial Gastro & General Hospital, 78-79 Dhuleshwar Garden Behind HSBC bank, Sardar Patel Marg C-Scheme, Japur-302001, Rajasthan, India	S. R. Kalla Memorial Ethical Committee For Human Research, S.R. Kalla Memorial Gastro & General Hospital, 78-79 Dhuleshwar Garden Behind HSBC bank, Sardar Patel Marg C-Scheme, Japur-302001, Rajasthan, India ECR/8/INST/Raj/2013/RR-19	Dr. Mukesh Kalla
2.	Shree Giriraj Multispeciality Hospital, A Unit of Shree Giriraj Lifecare Private Limited, 150 feet Ring Road, 27 Navjyot Park main Road, Rajkot-360005, Gujarat, India	Shree Giriraj Hospital Research Ethics Committee, Shree Giriraj Multispeciality Hospital, A Unit of Shree Giriraj Lifecare Private Limited, 150 feet Ring Road, 27 Navjyot Park main Road, Rajkot-360005, Gujarat, India ECR/74/INST/GJ/2013/RR-19	Dr. Mayank Rameshchandra Thakker
3.	Super Speciality Hospital, Attached to SMS Medical College, Vivekanand Marg, C- Scheme, Jaipur - 302001, Rajasthan India	Institutional Ethics Committee SMS Medical College & Attached Hospital, Office of Ethics Committee, Second Floor, New Academic Block, SMS Medical College, Jaipur-302004, Rajasthan, India ECR/26/Inst/RJ/2013/RR-19	Dr. Dhananjai Agrawal
4.	Nil Ratan Sircar Medical College and Hospital, 138, AJC Bose Road, Kolkata-700014, West Bengal, India	NRS Medical College, Nil Ratan Sircar Medical College and Hospital, 138, AJC Bose Road, Kolkata-700014, West Bengal, India ECR/609/Inst/WB/2014/RR-20	Dr. Badal Kumar Sahu
5.	JSS Hospital, Mahatma Gandhi Road, Ramachandra Agrahara, Mysore-570004, Karnataka, India	Institutional Ethics Committee, JSS Medical College and Hospital, 3 rd Floor, JSS Medical College, Mysore-570015, Karnataka, India ECR/387/Inst/KA/2013/RR-22	Dr. Tejeswini C J

File No. CT/14/23-DCG(I)

6.	Indrapratha Apollo Hospitals Sarita Vihar, Mathura Road, New Delhi-110076	Institutional Ethics Committee-Clinical Studies, Indrapratha Apollo Hospitals Sarita Vihar, Mathura Road, New Delhi-110076 ECR/5/Inst/DL/2013/RR-6/RR-19	Dr. Viny Kantroo
7.	BAPS Pramukh Swami Hospital, Shri Pramukh Swami Maharaj Marg, Adajan Char Rasta, Surat-395009, Gujarat, India	BAPS Pramukh Swami Hospital Institutional Ethics Committee, BAPS Pramukh Swami Hospital, Shri Pramukh Swami Maharaj Marg, Adajan Cross Road, Adajan, Surat-395009, Gujarat, India ECR/639/Inst/GJ/2014/RR-2020	Dr. Parshottam G. Koradia
8.	B.J. Government Medical College & Sassoon General Hospitals, Sassoon Road, Somwar Peth, Pune-411001, Maharashtra, India	IEC B.J.G.M.C and Sassoon General Hospital, Sassoon Road, Station Road, Pune, Maharashtra-411001, India ECR/433/Inst/MH/2013/RR-16	Dr. Rohidas Tanku Borse
9.	Regency Health Super-Speciality Hospital, Tedhi Pulia, Ring Road, Khurram Nagar, Lucknow-226022, Uttar Pradesh, India	Institutional Ethics Committee Regency Hospital Regency Hospital Kursi Road Khurram Nagar Lucknow Utar Pradesh - 226022 ECR/1719/Inst/UP/2022/RR-21	Dr. Deepak Dewan
10.	AIMS Hospital, P/72, Milap Nagar, MIDC, Dombivli, (E), 421203, Mumbai, Maharashtra, India	Suraksha Ethics Committee, AIMS Hospital, P/72, Milap Nagar, MIDC, Dombivli, (E), 421203 ECR/644/Inst/MH/2014/RR-20	Dr. Varade Deepak Bhanudas
11.	KLES Dr Prabhakar Kore Hospital & Medical Research Centre, Nehrunagar, Belagavi-590010, Karnataka, India	Institutional Ethics Committee, KLE University's, KLE Dr. PK Hospital & MRC, Nehrunagar, Belagavi-590010, Karnataka, India ECR/211/Inst/KA/2013/RR-19	Dr. Madhav Prabhu
12.	Shri Atal Bihari Vajpayee Medical College and research Institute Bowring and Lady Curzon Hospital, Lady Curzon Road, Shivajinagar Bangalore 560001, India	Ethics Committee of Shri Atal Bihari Vajpayee Medical College and research Institute Lady Curzon Road, Shivajinagar, Bangalore 560001, India ECR/1482/Inst/KA/2020	Dr. Prabhu Subramani

File No. CT/14/23-DCG(I)

13.	Nirmal Hospital Pvt. Ltd., Ring Road, Surat-395002	Nirmal Hospital Private Limited Ethics Committee, Nirmal Hospital Pvt. Ltd., Ring Road, Surat-395002 ECR/390/Inst/GJ/2013/RR-19	Dr. Kapil Thakkar
-----	---	---	-------------------
